Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography

Philipp Pichler1, Emel Pichler-Cetin, Markus Vertesich

  • 1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria. philipp.pichler@meduniwien.ac.at

Insights

Ivabradine effectively lowers heart rate for coronary CT angiography, showing a significantly smaller decrease in systolic blood pressure compared to metoprolol. This makes ivabradine a potentially safer option for patients undergoing this imaging procedure.

Area of Science:

  • Cardiology
  • Radiology
  • Pharmacology

Background:

  • Heart rate (HR) and image quality in coronary computed tomography angiography (CCTA) are correlated.
  • Beta-blockers are commonly used to reduce HR but can negatively impact cardiac contractility.
  • Ivabradine is a selective HR-lowering agent that does not affect cardiac contractility or conduction.

Purpose of the Study:

  • To compare the efficacy and safety of ivabradine versus metoprolol for HR reduction prior to CCTA.
  • To assess the impact of these agents on blood pressure (BP) during CCTA premedication.

Main Methods:

  • A randomized trial involving 120 patients undergoing CCTA.
  • Patients received either oral ivabradine (15 mg) or metoprolol (50 mg) as premedication.
  • HR and BP were measured before and after premedication; comparisons were made between groups.

Main Results:

  • Both ivabradine and metoprolol significantly reduced HR and diastolic BP, with no significant difference between groups.
  • Ivabradine resulted in a significantly smaller decrease in systolic BP compared to metoprolol (p <0.001).
  • In patients on long-term beta-blockers, ivabradine achieved greater HR reduction and less systolic BP decrease than metoprolol.

Conclusions:

  • Ivabradine provides sufficient HR reduction for CCTA.
  • Ivabradine demonstrates a superior safety profile regarding systolic BP depression compared to metoprolol.
  • Ivabradine is a viable alternative for HR control in CCTA, especially in patients sensitive to BP changes.

Related Concept Videos

Imaging Studies for Cardiovascular System V: CT01:28

Imaging Studies for Cardiovascular System V: CT

Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...